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Summary Inter-individual and cell-cell variability of repair of 06-alkylguanines (06-AlkGua) in nuclear
DNA was studied at the single-cell level in peripheral lymphocytes from healthy donors and in leukaemic cells
isolated from patients with chronic lymphatic leukaemia (CLL) or acute myeloid leukaemia (AML). Cells were
pulse exposed to N-ethyl- or N-(n-)butyl-N-nitrosourea in vitro, and 06-AlkGua residues in DNA were
quantified using an anti-(O6-AlkGua) monoclonal antibody and electronically intensified fluorescence. The
kinetics of 06-AlkGua elimination revealed considerable inter-individual differences in 06-ethylguanine (O6_
EtGua) half-life (ti) values in DNA, ranging from 1.5 to 4.5 h (five AML patients), from 0.8 to 2.8 h (five CLL
patients) and from 1.2 to 7.3 h (five healthy donors). The elimination from DNA of equimolar amounts of
06-butylguanine was generally 3-5 times slower in comparison with 06-EtGua. The t, values of individual
samples varied in parallel for both DNA alkylation products. Upon preincubation with 06-benzylguanine, the
activity of the DNA repair protein 06-alkylguanine-DNA alkyltransferase (AT) in both lymphocytes and
leukaemic blasts was reduced to <1%. However, while the rate of 06-EtGua elimination from DNA was
decelerated it was not abolished, suggesting the possible involvement of additional repair systems that might
be co-regulated with AT. Within individual samples, no major cell subpopulations were observed whose repair
kinetics would differ significantly from the remaining cells.
Resistance to chemotherapeutic drugs and radiation
represents a major obstacle in human cancer therapy. Since
DNA is the most important target of many cytotoxic agents,
the capacity for repair of specific, drug-induced DNA lesions
may be an important determinant in the response of cancer
cells to treatment, in addition to other mechanisms, such as
drug transport and detoxification (reviewed, for example, by,
Epstein, 1990; Burt et al., 1991; Ross & Brown, 1992). How-
ever, comparatively little is known about the DNA repair
capacity of malignant cells derived from patients. This is
mainly because of the lack of sufficiently sensitive methods of
quantifying specific DNA adducts and the rate of their
elimination from DNA in small cell samples or in individual
cells.
Mono- or bifunctional alkylating agents such as nitro-
soureas, procarbazine, cyclophosphamide, mitomycin C,
BCNU, busulphan and chlorambucil form cytotoxic and
mutagenic DNA adducts via covalent bonds to nucleophilic
sites, preferentially at the N7- and 06-atoms of guanine (Col-
vin & Chabner, 1990). Guanine-06 alkylation products in
DNA are very efficiently repaired by a specific DNA alkyl-
transferase (AT; EC 2.1.1.63; Pegg, 1990) and, more slowly,
by alternative pathways such as base or nucleotide excision
(Boyle et al., 1986a, b; Bronstein et al., 1992a, b; Sibghat-
Ullah & Day, 1992).
In human cells, e.g. normal cells or cells derived from
tumours, autopsy material, surgical biopsies or fetal tissues,
significant differences in cellular AT protein levels among
different tissues have been reported (Gerson et al., 1986;
D'Incalci et al., 1988; Fornace et al., 1990; Vahakangas et al.,
1991; Chen et al., 1992; Wani et al., 1993). Moreover, con-
siderable inter-individual variability has been observed for a
given type of cells (Kyrtopoulos et al., 1990; Strauss, 1990;
Citron et al., 1991; Redmond et al., 1991). Thus, in peri-
pheral human lymphocytes inter-patient variations in AT
levels up to a factor of 9 have been reported (Sagher et al.,
1988; Gerson, 1989; Lee et al., 1991; Panella et al., 1992).
Plausible relationships have been proposed between cell type
and individual sensitivity to the cytotoxic effects of alkylating
or chloroalkylating agents on the one hand and the levels of
cellular AT activity on the other (Brent et al., 1985; Gerson
et al., 1988; Gerson & Trey, 1988; Dolan et al., 1989; Pieper
et al., 1991; Panella et al., 1992). Other experimental data
indicate that cellular AT activity may not always be the most
critical determinant of cellular resistance to alkylating agents
such as CNUs or EtNU (Silber et al., 1992; Bobola et al.,
1993; Chen et al., 1993). Godfrey et al. (1992) have suggested
that cellular resistance to the cytotoxic effect of 06-alkyl-
guanines (06-AlkGua) persisting in DNA could also be
caused by mechanisms other than DNA repair, such as 'post-
replication recovery'.
An increasing body of evidence indicates that DNA
damage and the repair of specific DNA lesions is hetero-
geneous among individual cells (e.g. in biopsy material,
Scherer et al., 1989; Wani et al., 1993) and throughout
genomic DNA (Bohr, 1991; Le Doux et al., 1991; Thomale et
al., 1993). However, only very recently, sufficiently sensitive
analytical methods have become available which permit us to
quantify specific drug-induced DNA lesions in defined gene
sequences (Hochleitner et al., 1991; Zhen et al., 1992) and in
single cells (Frankfurt et al., 1990; Van Delft et al., 1991;
Seiler et al., 1993). In the present study, we have applied a
newly developed, monoclonal antibody (MAb)-based immuno-
cytological assay (ICA; Seiler et al., 1993) to measure the
repair kinetics of 06-AlkGua in the nuclear DNA of indivi-
dual human lymphocytes and leukaemic blasts after pulse
exposure to N-alkyl-N-nitrosoureas. This class of compounds
is particularly suitable as prototype substances because the
reaction kinetics and all major reaction products with DNA
are well characterised. Moreover, we have determined the
influence of 06-benzylguanine (06-BeGua), an inhibitor of
cellular AT activity (Dolan et al., 1990), on the persistence of
06-alkylguanines in the DNA of these cells.
Materials and methods
Isolation ofperipheral tymphocytes or leukaemic blasts
Heparinised blood (10 ml) obtained from patients with AML
or CLL before chemotherapy or from healthy donors was
layered onto 10 ml of Ficoll-Hypaque and centrifuged for
25 min at 200 g at room temperature (RT). Cells at the
interphase were removed, washed twice in phosphate-buffered
saline (PBS) and resuspended in RPMI-1640 medium (Gibco)
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containing 10% fetal calf serum (FCS; Seromed). Samples
contained > 90% lymphocytes and/or blast cells as deter-
mined by light microscopy. Cell numbers were adjusted to
5 x 105ml-' and cultures were kept at 37°C in a humidified
atmosphere containing 10% carbon dioxide.
In vitro cultivation ofcells andpulse exposure to
N-alkyl-N-nitrosoureas
For pulse exposure of cells to N-ethyl-N-nitrosourea (EtNU; Roth) or N-(n-butyl)-N-nitrosourea (BuNU; Serva) the cul-
ture medium was exchanged for prewarmed (37°C) PBS sup- plemented with Ca2" (9001LM), Mg2" (4901EM) and HEPES
(25mM), pH 7.25. Stock solutions of EtNU and BuNU
(100 mgml-' water-free DMSO) were prediluted in serum-
free 'acidic' RPMI medium (adjusted to pH 6.0 with carbon
dioxide) and added to the cells to give final concentrations of
100Igml'l EtNU or 300ptgml-' BuNU. After 20min of
incubation at 37°C, cells were washed twice with PBS and
resuspended in fresh, prewarmed medium for further cultiva-
tion.
Immediately after exposure to N-alkyl-N-nitrosourea (to), and after 1.5, 3, 6, 9 and 24h, cell aliquots were withdrawn
from the cultures, washed with PBS and placed onto micro-
scope slides. Thereafter, slides were air dried, fixed for 30 s in
cold (-20C) acetone, evaporated at 4°C and stored at
-800C.
Immunofluorescence staining
Immunofluorescence staining of 06-EtGua and 06-BuGua in
nuclear DNA was performed as described (Seiler et al.,
1993). Briefly, cells on slides were fixed in methanol (15 min,
RT), rehydrated in 2 x SSC and treated with RNAse A
(200 Agml-'; Sigma) and RNAse T1 (50 units ml-'; Boeh-
ringer Mannheim) for 1 h at 370C. Cells were then washed in
0.14 M sodium chloride and cellular DNA was denatured by
treatment with 70 mM sodium hydroxide in 0.14mM sodium
chloride (5 min; 0WC). After washing (PBS/i % BSA) and
preincubation with PBS/20% BSA (20 min; RT), cells were
incubated with anti-(06-AlkGua)-specific MAb ER-17
(Eberle, 1989; 0.2 ;g ml-' PBS-BSA; 16 h; 40C), washed
again and stained with a goat anti-rat IgG F(ab)2 fragment conjugated with rhodamine isothiocyanate (TRITC; 2 jig ml-' PBS-BSA; Dianova) for 45 min at 370C.
Nuclear DNA was counterstained for 10 min with 4,6-
diamidino-2-phenylindole (DAPI; Serva; 3 x 10- M in PBS), and slides were mounted in PBS containing 0.05 MTris-HCI,
0.033 M 1,4-dithioerythritol (DTE; Serva), 30% glycerol and
10% Elvanol, pH 8.2, to reduce dye fading.
Quantification of06-EtGua and 06-BuGua in nuclear DNA of individual cells
A Zeiss photomicroscope III set up for epifluorescence with
an HBO 100 W mercury lamp and Zeiss standard filter com-
binations 02 (for DAPI) and 14 (for TRITC) were used.
Nuclear fluorescence signals were amplified by an electronic
intensifier (Proxifier BV2532; Proxitronic), recorded by a
video camera (Vidicon C 1000-12 SIT; Hamamatsu) and fed
into a multiparameter image analysis program (ACAS Cytometry Analysis System; Ahrens). This program enables
image integration at low signal/noise ratios and separate quantification of both antibody and DNA fluorescence from
the same cell (Seiler et al., 1993). Thresholds were set to
discriminate between background and DNA staining signals
to determine image points to be included in the evaluation.
Fluorescence intensities (DAPI and TRITC) of selected pixels
were recorded as integrated signals (average signal x number
of selected pixels) per nucleus. Signals were corrected for
cellular DNA content and average TRITC fluorescence inten-
sities were computed per 100-200 nuclei.
Determination ofATactivity in cell extracts
AT activity in cell extracts was determined essentially as
described by Pegg et al. (1982). Briefly, cells were suspended
in extraction buffer (50 mM Tris-HCl, pH 7.8, 100 mM
sodium chloride, 1 mM DTT, 1 mM EDTA, 5% glycerol),
sonicated (3 x 5 s; 0°C) and cell debris was removed by
centrifugation (Omin; 12,000g; O°C) as previously described
(Nehls & Rajewsky, 1990). Substrate DNA was prepared by
methylation of calf thymus DNA in vitro with N-[3H]methyl-
N-nitrosourea (Amersham-Buchler; specific activity,
II Ci mmol '). [3H]methyl-DNA containing 100 fmol of o6-
methylguanine per assay was incubated with different
amounts of cell extracts (0.1-I mg of protein per assay;
30min at 37°C). Methylated bases were released from DNA
by acid hydrolysis, separated by high-performance liquid
chromatography (HPLC) and [3H]methylpurines in the
eluates were quantified by liquid scintillation spectrometry.
Results
Repair of06-ethylguanine in the DNA ofhuman lymphocytes
and leukaemic blasts afterpulse exposure to EtNU in vitro
Cellular capacity to eliminate 06-EtGua from nuclear DNA
was determined in human peripheral lymphocytes or blast
cells derived from healthy donors or from patients with CLL
or AML. At different times after 20 min exposure of cells to
non-cytotoxic doses of EtNU, the amount of O6-EtGua in
the nuclear DNA ofindividual cells was determined by quan-
titative immunofluorescence image analysis (immunocyto-
logical assay, ICA; Seiler et al., 1993). As shown in Figure 1,
fluorescence signals (red) derived from binding of MAb ER-
17 to 06-EtGua and a second TRITC-labelled anti-(rat Ig)
antibody and (blue) from DAPI-stained nuclear DNA were
obtained from cells immediately after EtNU exposure
(100 fig ml-'; Figure la) and after 6 h repair time (Figure
Ib). No significant TRITC fluorescence was recorded from
untreated control cells from the same donor (Figure Ic).
Quantitative image analysis of fluorescence signals emitted
by the TRITC-labelled antibody and from DAPI-stained
DNA of individual cells resulted in normal distributions for
both types of signals (Figure 2a and b) and a positive cor-
relation (Spearman rank coefficient of correlation, 0.76,
PK0.0 1; n = 100; Figure 2c). Measurements of antibody
fluorescence (corrected for DNA content) per 100 cells
analysed at different times after EtNU exposure (t0h,t6h, t24h;
Figure 3) showed coefficients of variation (CV) between 22
and 35. Curves for the kinetics of elimination of 06-EtGua
from nuclear DNA were established using mean values for
100 cells analysed per time point. The kinetics of removal of
06-EtGua from the DNA of lymphocytes isolated from a
CLL patient is shown in Figure 4. Of -24,000 06-EtGua
residues formed on average per diploid genome, these cells
eliminated
- 12,000 adducts (50%) within 3 h after EtNU
exposure, and -22,000 adducts (90%) within 17 h. As deter-
mined by flow cytometry in parallel, 95% of cells were in the
G, phase of the cell cycle or in Go (data not shown).
The stability of the cellular 'repair phenotype' and the
reproducibility of the analytical procedure were examined by
repeated analyses of lymphocytes isolated from the same
healthy individuals on consecutive days. Only minor intra-
individual variations in the half-life (t1) values for 06-EtGua
were observed (Figure 5). However, very large differences
regarding the persistence of 06-EtGua in DNA were found,
when lymphocytes or blast cells from different individuals
were analysed. Thus t values varied between 1.2 h and 7.3 h
among five healthy donors, between 1.5 h and 4.5 h among
five AML patients and between 0.8 h and 2.8 h among five
CLL patients (Figure 6). In none of the cases major (> 10%)
cell subpopulations were found that differed significantly
from the remaining cells with respect to 06-EtGua repair:
fluorescence signals (corrected for DNA content) showed
approximately normal distribution at all time points, with a700 J. THOMALE et al.
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Figure 1 Visualisation of 06-EtGua residues in DNA of CLL lymphocytes exposed to EtNU in vitro. Micrographs: 1, phase contrast; 2, fluorescence of DNA stained with DAPI (blue); 3, fluorescence [immunostaining with anti-(06-EtGua) MAb ER-17 and TRITC-labelled anti-Ig second antibodies (red)] a, Immediately after 20 min exposure to EtNU (100,gml-L); b, 6 h after exposure to EtNU; c, Untreated control cells from the same donor.
tendency to slightly increased variations (CV 30-50%) at
lower DNA adduct levels.
The contribution of the suicidal DNA repair protein AT to
the elimination of 06-EtGua from DNA was determined by
1.5 h preincubation of cells with the AT inhibitor o6-
benzylguanine (25 rLM) prior to EtNU exposure. The repair
kinetics oflymphocytes from a normal donor (Figure 7a) and
from a CLL patient (Figure 7b and Table I) demonstrate
that 06-EtGua elimination from DNA was significantly
decelerated but not completely blocked under these condi-
tions. Normal lymphocytes (donor J.T.) exhibited rapid
elimination of 06-EtGua from DNA in the absence of o6-
BeGua. Comparison of toh values of untreated and o6-
BeGua pretreated cells showed that >60% of all 06-EtGua
residues formed in DNA were already repaired during the
20min period of EtNU exposure. Under conditions of AT
inhibition by 06-BeGua prior to EtNU exposure and
throughout the entire experimental period, ti was prolonged
to 4 h. When 06-BeGua was withdrawn from the culture
medium after EtNU exposure, repair was accelerated
(t1 = 2 h). The AT activity measured in extracts from lym-
phocytes kept in normal medium was 516 fmol permg of
protein (Table I). After preincubation of lymphocytes with
06-BeGua (25gtM; 1.5 h) no AT activity was detectable in
these extracts (detection limit of the assay: 2.5 fmol per mg of
protein). Very rapid recovery of AT activity in extracts was
found after shifting these cells back to normal culture
medium (145 and 320 fmol per mg of protein, after 1.5 h and
3 h respectively representing 28% and 62% of the untreated
controls). The stability of the AT inhibitor under the experi-
mental conditions used was determined by incubating o6_
BeGua with cell culture medium or cell extracts, for 24 h and
48 h respectively. No degradation of 06-BeGua was observed
by HPLC/diode array analysis.
Under normal culture conditions, lymphocytes isolated
from a CLL patient (F.G.) eliminated 12% of 06-EtGua
residues from DNA during the 20 min ethylation period, and
50% within 2 h (Figure 7b). Under AT blocking by o6-
BeGua before, during and after ethylation, 06-EtGua was
still eliminated from DNA, but less rapidly by a factor of 9
(t-18 h) as compared with untreated cells (t1 = 2 h; see
Table I).
Elimination of06-BuGuafrom the DNA oflymphocytes or
leukaemic blasts afterpulse exposure to BuNU
For selected cell samples the persistence of 06-BuGua in
nuclear DNA was determined in parallel. To induce an
equimolar amount of O6-guanine alkylation in DNA by
BuNU (Saffhill, 1984), cells were exposed to 300 tgml-1
BuNU for 20 min (standard conditions), resulting in
-25,000 06-BuGua residues per diploid genome (as deter-
mined in DNA isolated from cell aliquots by immunoslot-
blot analysis; data not shown). The elimination of06-BuGua
and 06-EtGua from the DNA of AML blast cells exposed to
BuNU and EtNU, respectively, followed different kinetics.
While 06-EtGua was repaired with typical biphasic kinetics
(t1 = 3.4h), 06-BuGua elimination was much slower
(t1 = 13.5 h), exhibiting linear repair characteristics (Figure
8). ti values for 06-BuGua were generally higher by a factor
of 3-5 in comparison with the elimination of equimolar
amounts of 06-EtGua (as shown for various cell samples in
Figure 9). In one case of CLL, however, elimination of both
alkylation products was much more rapid (tj<l h),
exhibiting no difference between the repair of 06-EtGua and
06-BuGua within the time intervals analysed.
Discussion
Although the potential of DNA repair in mediating the
resistance of cancer cells to DNA-reactive drugs has been
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recognised for a long time, little is known so far about its
clinical significance. This is mainly because of the lack of
sensitive and reliable assays to quantify specific DNA lesions
in small samples of cells from cancer patients. In the present
study, we have applied a recently established MAb-based
immunoanalytical assay for the quantification of specific
lesions in the nuclear DNA of individual cells (Seiler et al.,
1993) to measure directly the kinetics of elimination (repair)
of 06-AlkGua residues from DNA in human peripheral lym-
phocytes and leukaemic blasts.
Among the lymphocytes or blast cells isolated from indi-
vidual donors, comparatively uniform intercellular formation
and repair of 06-EtGua in DNA were observed after pulse
exposure to EtNU in vitro. Within groups of 100 cells
analysed per time point, major (> 10%) cell subpopulations
differing significantly from the remaining cells with respect to
O6-EtGua elimination from nuclear DNA were not detected.
Repair variants present at lower frequencies may be
identified by adapting the immunoanalytical procedure used
here to flow cytometric techniques.
The 06-EtGua 'repair phenotype' of the normal lym-
phocytes of a given individual was rather stable, i.e. no major
variations were observed regarding the persistence of o6-
EtGua in cells isolated from the same donor at different
times over a period of 1 week, although the distributions of t1
values became somewhat broader (± 25% of the mean) dur-
ing long-term observations for up to several months. In
contrast, the persistence of 06-EtGua in nuclear DNA of
lymphocytes and leukaemic blasts exhibited wide inter-
individual variability. Thus, initial ti values for 06-EtGua
differed by a factor of 8 between five samples of normal
lymphocytes and 10-fold in all samples analysed. At least in
part, these observations are likely to reflect different levels of
AT activity in human peripheral lymphocytes (Cohen &
C
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Figure 3 Histograms of antibody fluorescence signal distribu-
tions (corrected for DNA content and background fluorescence)
in AML blasts. One hundred cells per sample were analysed at
b different time points (t0 h, t6h, t24h) after exposure to EtNU.
Ordinate, number ofcells; abscissa, relative fluorescence intensity.
x, mean values ofTRITC fluorescence signals corrected for DNA
fluorescence; s.d., standard deviation; CV, coefficient of varia-
tion.
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Figure 2 Histograms of (a) antibody (TRITC-labelled) and (b)
DNA (DAPI-stained fluorescence signals from 100 CLL lympho-
cytes stained and analysed after 20 min exposure to EtNU
(100 jig ml-l; see Figure 1). c, Correlation of TRITC- and DAPI-
derived signals in individual cells (Spearman rank correlation
0.76, PO0.01, n=l00).
Figure 4 Kinetics of 06-EtGua elimination from the DNA of
CLL lymphocytes exposed to EtNU (100plgml-'; 20min) in
vitro. Mean values of relative nuclear fluorescence signals (see
Figure 3) of 100 cells per time point are plotted. Time for
elimination of 50% and 90% of 06-EtGua residues present in
DNA after 20min of exposure to EtNU (to) were determined
graphically. (Linear intrapolation between 6 and 24 h may
overestimate the t9o% value.)
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Leung, 1986; Sagher et al., 1988; Strauss, 1990; Lee et al.,
1991; Souliotis et al., 1991)
After blocking cellular AT activity by preincubating cells
with 06-BeGua, elimination of 06-EtGua from DNA of nor-
mal and leukaemic lymphocytes was decelerated con-
siderably, but not entirely abolished. Thus, after reducing the
level of active AT by 06-BeGua to 1% of untreated controls
(Table I), 06-EtGua was still repaired with t, = 4 h in a
sample of normal lymphocytes (Figure 7). This observation
suggests that, in distinct cell samples, the kinetics of O6-
EtGua elimination from DNA may result from more than
one repair mechanism: a very fast-reacting, 06-BeGua-
sensitive component (AT) and a second, more slowly acting
system unaffected by 06-BeGua. It remains to be determined
whether this second component represents a 'back-up'
excision repair pathway or another repair mechanism.
It has been shown that the bacterial UVR excision repair
complex efficiently eliminates 06-methyl- and -ethylguanine
from DNA in vivo (Samson et al., 1988). Experiments
designed to detect a similar activity in extracts of rodent and
human cells using double-stranded oligonucleotides contain-
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Figure 5 Intra-individual variation of repair capacity (t4 values)
for 06-EtGua in nuclear DNA of lymphocytes. Cells from three
healthy donors (P1, P2, P3) were isolated on consecutive days,
exposed to EtNU in vitro, and the kinetics of 06-EtGua elimina-
tion from DNA was determined as described in Figures 2 and 3.
t mean values ± s.d.: P1 ( = ), 2.9± 0.4; P2, ( m ) 1.8 + 0.14;
P3, (_) 4.2± 0.3.
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Figure 6 Inter-individual variation of repair capacity for 06_
EtGua in DNA as determined in lymphocytes or leukaemic
blasts. Cells isolated from five healthy donors ( ), from five
CLL patients ( M ) or from five AML patients ( LI) were
exposed to EtNU in vitro. The content of 06-EtGua in DNA was
quantified by immunofluorescence analysis at different time
points (l0h; t,.5h; t3h; t6h; t24h) (see Figures 2 and 3); time intervals
(tj) for removal of 50% of 06-EtGua residues from nuclear DNA
were determined from the repair kinetics.
Time after EtNU pulse (h)
Figure 7 Influence of the AT inhibitor 06-benzylguanine on the
elimination from DNA of 06-EtGua in lymphocytres in vitro.
Lymphocytes isolated from a healthy donor (a) and from a CLL
patient (b) were exposed to EtNU (100pg ml-') in vitro and
analysed for their 06-EtGua content in DNA at different times as
described (Figures 2 and 3). Throughout the experiment cells
were either kept in normal RPMI medium (0) or in medium
supplemented with 06-benzylguanine (25 jiM) 1.5 h prior to EtNU
exposure and throughout the entire experimental period (A), or
pretreated with 06-benzylguanine for 1.5 h only, followed by a
change to normal medium after exposure to EtNU (A).
Table I Persistence of 06-ethylguanine in the DNA of lymphocytes after pulse
exposure to EtNU: influence of AT inhibition by 06-benzylguanine
Repair time
half-life (t1) of
AT activity of extracts 06-EtGua in nuclear DNA
Cells (± 06-BeGua) (fmolmg-' protein) (h)
NL
Untreated 516 0.5
Pretreated only 2.5 2.0
Pre- and post-treated 2.5 4.0
CLL
Untreated 76 2.0
Pre- and post-treated 2.5 17.0
NL, normal lymphocytes; CLL, CLL lymphocytes (for experimental conditions,
see Figure 7).
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Figure 8 Kinetics of elimination of 06-EtGua (0) and o6-
BuGua (0) from the DNA of leukaemic blasts in vitro. Cells
were isolated from an AML patient, exposed to EtNU
(100igrml-') or to BuNU (300pjgml-') and analysed for the
content of 0-EtGua or 06-BuGua by immunofluorescence (see
Materials and methods). Each time point represents the mean
value of fluorescence signals from 100 cells.
ing 06-MeGua opposite cytosine have thus far failed (Karran
& Bignami, 1992; Sibghat-Ullah & Day, 1992; Branch et al.,
1993). It is still unclear whether an excision repair mechanism
defective in xeroderma pigmentosum may complement AT-
mediated repair of 06-EtGua, as postulated by Bronstein et
al. (1992a, b).
The characterisation of multiple, overlapping DNA repair
systems for the elimination of alkylation damage from the
DNA of mammalian cells may help us to understand incon-
sistent results on the relevance of AT activity levels for the
resistance of cancer cells to the cytotoxicity of mono- and
bifunctional alkylating agents. In a variety of human primary
tumour cells, tumour cell lines and human xenografts in
rodents, an inverse correlation has been observed between
cellular AT activity and cell killing by this class of anti-
cancer drugs (Brent et al., 1985; Cohen & Leung, 1986;
Gerson et al., 1988a, b; Dolan et al., 1989, 1990, 1991;
Gonzaga et al., 1992; Mitchell et al., 1992; Panella et al.,
1992; Baer et al., 1993). On the other hand, different levels of
AT activity did not significantly influence cellular sensitivity
to BCNU or EtNU in a number of human cell types, e.g.
glioblastoma cell lines, brain tumours or lymphocytes (Silber
et al., 1992; Walker et al., 1992; Bobola et al., 1993; Muller
et al., 1993).
Although 06-BuGua may be eliminated from DNA by
purified mammalian AT protein in vitro (Morimoto et al.,
1985), the predominant involvement of an excision repair
mechanism in the elimination of this lesion from DNA in
vivo is suggested by experimental data obtained by Boyle et
al. (1986a, b). Moreover, these authors have shown that
excision repair activity in human tumour cell lines is cor-
related with the cells' ability to excise bulky DNA lesions.
Therefore, determination of the rate of 06-BuGua repair can
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Figure 9 Comparison of cellular repair capacities for 06-EtGua
(Eli) and 06-BuGua ( ) in the DNA of lymphocytes and
leukaemic blasts. Cells were isolated from patients with CLL or
AML or from healthy individuals, and aliquotes were exposed to
EtNU (I00 lg ml-) or BuNU (300jigml-'), in vitro. The con-
tent of 0-alkylguanines in nuclear DNA at different times after
alkylation was determined by immunofluorescence analysis in 100
cells per sample. The t4 values for the content of 06-alkylguanines
in nuclear DNA were deduced from the elimination curves. (In
the case of the CLL specimen, both adducts were below the
detection limit at tl.5h; the t1 values were estimated to be
<1 h.)
provide information on the possible dependence of cellular
drug resistance on DNA excision repair capacity. In four out
of five cell samples analysed for repair of 06-EtGua and
06-BuGua in parallel, we found similar long persistence of
the butyl residue (t1 values between 6 and 16 h). However,
one sample of CLL lymphocytes exhibited extremely rapid
elimination of both DNA alkylation products (t1 <1 h).
Interestingly, these cells were isolated from a patient who
later proved to be highly resistant to chemotherapy with
alkylating agents. These findings, together with the observa-
tion that cellular AT pools and 'residual' repair capacities
after AT blocking are correlated (Table I), may indicate an
(incidential) coregulation of different DNA repair systems.
The aim of the present study was to develop a sensitive
and reliable technique for determining, at the single-cell level,
the capacity of cancer cells derived from patients to repair
specific drug-induced DNA lesions. Because of the small
number of samples analysed, we are not yet able to relate the
DNA repair capacity of malignant cells to clinical status.
Further studies should, therefore, apply this immunocyto-
logical assay for the differential repair of critical DNA
lesions to a larger number of human cell samples in order to
correlate the results to in vitro drug sensitivity profiles to the
effects of different drug resistance (DNA repair) modifiers
and to clinical data. These analyses will contribute to a better
appreciation of the relevance of DNA repair mechanisms to
therapy resistance and to the design of individualised
regimens for cancer chemotherapy.
This work was supported by the Dr Mildred Scheel, Stiftung fur
Krebsforschung (W69/91/Mill). We thank Bettina Baumgart for
excellent technical assistance.
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